{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:24:42Z","timestamp":1758475482005,"version":"3.37.3"},"reference-count":60,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1124\/dmd.113.053991","type":"journal-article","created":{"date-parts":[[2013,9,26]],"date-time":"2013-09-26T04:26:16Z","timestamp":1380169576000},"page":"2166-2174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cytochrome P4503A Does Not Mediate the Interaction between Methadone and Ritonavir-Lopinavir"],"prefix":"10.1016","volume":"41","author":[{"given":"Evan D.","family":"Kharasch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi","family":"Stubbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.053991_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.clpt.6100104","article-title":"Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice","volume":"81","author":"Bailey","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/jac\/dkr596","article-title":"Lopinavir\/ritonavir significantly influences pharmacokinetic exposure of artemether\/lumefantrine in HIV-infected Ugandan adults","volume":"67","author":"Byakika-Kibwika","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.113.053991_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1742-7843.2010.00628.x","article-title":"Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation","volume":"108","author":"Chang","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.053991_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jpain.2008.10.008","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J Pain"},{"key":"10.1124\/dmd.113.053991_bib5","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/339541","article-title":"Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir","volume":"34","author":"Clarke","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.113.053991_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.clpt.2006.09.012","article-title":"ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment","volume":"80","author":"Crettol","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.antiviral.2009.07.017","article-title":"Pharmacokinetics and drug-drug interactions of antiretrovirals: an update","volume":"85","author":"Dickinson","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1124\/dmd.113.053991_bib8","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clpt.2004.02.008","article-title":"Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers","volume":"76","author":"Ding","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","article-title":"Methadone\u2014metabolism, pharmacokinetics and interactions","volume":"50","author":"Ferrari","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.113.053991_bib10","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1345\/aph.1K615","article-title":"Induction effects of ritonavir: implications for drug interactions","volume":"42","author":"Foisy","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.113.053991_bib11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","article-title":"Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4","volume":"47","author":"Foster","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053991_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/chir.10303","article-title":"Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19","volume":"16","author":"Gerber","year":"2004","journal-title":"Chirality"},{"key":"10.1124\/dmd.113.053991_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00004714-199908000-00001","article-title":"Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction","volume":"19","author":"Greenblatt","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.113.053991_bib14","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1002\/jps.22655","article-title":"Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors","volume":"100","author":"Griffin","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.113.053991_bib15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.clpt.6100027","article-title":"Lopinavir\/ritonavir reduces bupropion plasma concentrations in healthy subjects","volume":"81","author":"Hogeland","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.113.053991_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/tx950116m","article-title":"Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes","volume":"9","author":"Iribarne","year":"1996","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.113.053991_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1521-0391.2009.00010.x","article-title":"Drug interactions between antiretroviral medications and medications used in the treatment of drug addiction: research needs","volume":"19","author":"Khalsa","year":"2010","journal-title":"Am J Addict"},{"key":"10.1124\/dmd.113.053991_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1213\/ANE.0b013e3181fec9a3","article-title":"Intraoperative methadone: rediscovery, reappraisal, and reinvigoration?","volume":"112","author":"Kharasch","year":"2011","journal-title":"Anesth Analg"},{"key":"10.1124\/dmd.113.053991_bib20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/ALN.0b013e3182423478","article-title":"Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A)","volume":"116","author":"Kharasch","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.113.053991_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2008.104","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib22","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/clpt.2008.102","article-title":"Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities","volume":"84","author":"Kharasch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib23","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/clpt.2011.59","article-title":"Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction","volume":"90","author":"Kharasch","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","article-title":"Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","article-title":"Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir\/indinavir","volume":"110","author":"Kharasch","year":"2009","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.113.053991_bib26","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1128\/AAC.01600-07","article-title":"Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir","volume":"52","author":"Kharasch","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.113.053991_bib27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcph.1","article-title":"Role of cytochrome P4502B6 in methadone metabolism and clearance","volume":"53","author":"Kharasch","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053991_bib28","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/clpt.2010.313","article-title":"Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil","volume":"89","author":"Kharasch","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clpt.2004.07.006","article-title":"Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0091270004269705","article-title":"Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination","volume":"45","author":"Kharasch","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053991_bib31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.clpt.6100237","article-title":"Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam","volume":"82","author":"Kharasch","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.12.009","article-title":"Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity","volume":"101","author":"Kharasch","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/dmd.113.053991_bib33","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/clpt.2011.276","article-title":"Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics","volume":"91","author":"Kharasch","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib34","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1124\/dmd.111.038646","article-title":"Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.053991_bib35","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.053991_bib36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/dmd.111.042705","article-title":"Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion","volume":"40","author":"Kirby","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.053991_bib37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","article-title":"CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction","volume":"18","author":"Levran","year":"2013","journal-title":"Addict Biol"},{"key":"10.1124\/dmd.113.053991_bib38","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1124\/dmd.113.053108","article-title":"The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir","volume":"41","author":"Lin","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.053991_bib39","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-010-0793-6","article-title":"The pharmacological treatment of opioid addiction\u2014a clinical perspective","volume":"66","author":"Lobmaier","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053991_bib40","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10096-007-0293-5","article-title":"Methadone-induced torsade de pointes after stopping lopinavir-ritonavir","volume":"26","author":"L\u00fcthi","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1124\/dmd.113.053991_bib41","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1124\/mol.107.041459","article-title":"Involvement of multiple efflux transporters in hepatic disposition of fexofenadine","volume":"73","author":"Matsushima","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.113.053991_bib42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/376907","article-title":"The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients","volume":"37","author":"McCance-Katz","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.113.053991_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict"},{"key":"10.1124\/dmd.113.053991_bib44","first-page":"CD003971","article-title":"Methadone for cancer pain","volume":"4","author":"Nicholson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/dmd.113.053991_bib45","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s11095-007-9251-2","article-title":"Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar","volume":"24","author":"Ortega","year":"2007","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.113.053991_bib46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.lfs.2010.09.012","article-title":"Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals","volume":"88","author":"Pal","year":"2011","journal-title":"Life Sci"},{"key":"10.1124\/dmd.113.053991_bib47","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1592\/phco.20.6.549.35162","article-title":"The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine","volume":"20","author":"Piscitelli","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.113.053991_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00952990.2010.540279","article-title":"Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence","volume":"37","author":"Saber-Tehrani","year":"2011","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1124\/dmd.113.053991_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2125.2008.03312.x","article-title":"Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment","volume":"67","author":"Shiran","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053991_bib50","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jbi.2006.10.004","article-title":"Surveillance of methadone-related adverse drug events using multiple public health data sources","volume":"40","author":"Sims","year":"2007","journal-title":"J Biomed Inform"},{"key":"10.1124\/dmd.113.053991_bib51","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/00126334-200308150-00016","article-title":"Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir\/ritonavir","volume":"33","author":"Stevens","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.113.053991_bib52","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/QAI.0b013e3181f52f0c","article-title":"Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans","volume":"55","author":"Sv\u00e4rd","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.113.053991_bib53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.106.117580","article-title":"Enantiomeric metabolic interactions and stereoselective human methadone metabolism","volume":"321","author":"Totah","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.053991_bib54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","article-title":"Role of CYP2B6 in stereoselective human methadone metabolism","volume":"108","author":"Totah","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1124\/dmd.113.053991_bib55","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/0091270006288733","article-title":"Time-dependent interaction between lopinavir\/ritonavir and fexofenadine","volume":"46","author":"van Heeswijk","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.113.053991_bib56","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/00002030-200305020-00023","article-title":"Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein","volume":"17","author":"Vishnuvardhan","year":"2003","journal-title":"AIDS"},{"key":"10.1124\/dmd.113.053991_bib57","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/JCP.0b013e318222b5dd","article-title":"CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer","volume":"31","author":"Wang","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.113.053991_bib58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5055\/jom.2005.0045","article-title":"Methadone-related deaths","volume":"1","author":"Webster","year":"2005","journal-title":"J Opioid Manag"},{"key":"10.1124\/dmd.113.053991_bib59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.clpt.6100452","article-title":"Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients","volume":"84","author":"Wyen","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.053991_bib60","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers","volume":"42","author":"Yeh","year":"2006","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624115632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.053991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:39:43Z","timestamp":1739907583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624115632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0090955624115632"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.053991","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytochrome P4503A Does Not Mediate the Interaction between Methadone and Ritonavir-Lopinavir","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.053991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}